
Ron Finklestien
Eli Lilly Expands Portfolio Through Partnership with Verve Gene Therapy
“`html Eli Lilly has acquired Verve Therapeutics for $1.3 billion, representing a 113% premium over Verve’s 30-day volume-weighted average price. Following the announcement on ...
GILD Stock Investment Strategies: Buy, Sell, or Hold?
“`html Gilead Sciences (NASDAQ: GILD) has faced a setback with an FDA clinical hold on its HIV treatment trials, GS-1720 and GS-4182, due to ...
Anticipating FedEx Stock Movements Ahead of Earnings Report
“`html FedEx (NYSE: FDX) is set to announce its fiscal Q4 2025 earnings on June 24, 2025. Analysts project earnings of $5.86 per share ...
Comparing Philip Morris and Alphabet: Which Stock Should You Choose?
“`html Key Facts: Google’s stock (GOOG) trades at a price-to-earnings (P/E) ratio of 19, while Philip Morris stock has a P/E ratio of 37. ...













